BioSpace News Archive

LUND, Sweden , Feb. 24, 2020 /PRNewswire/ -- BioInvent International AB (OMXS: BINV) will issue its interim report for the fourth quarter 2019 on Thursday February 27 at 7.30 a.m. CET , followed by an audiocast with teleconference at 8.30 a.m. CET , hosted by Martin Welschof, CEO and members of the management team. The presentation will be held in English. To participat

WAKEFIELD, Mass., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today the Company submitted a Material Transfer Agreement (MTA) with a leading U.S.-based virology laboratory to research its lead defensin mimetic drug candidate, Brilacidin as a potential novel coronavirus treatment. Brilacidin has demonstrated broad and robust antibacterial, anti-inflammatory and immunomodulatory properties in mul

Sharecare, the digital health company that helps people manage all their health in one place, today announced its acquisition of Visualize Health, a company that supports value-based healthcare and enables payers and providers to close gaps in patient care

Cancer cells are notorious for their genetic disarray. A tumor cell can contain an abundance of DNA mutations and most have the wrong number of chromosomes.

CUPE was thrilled to see the NDP introduce legislation to finally bring in universal, public, single-payer pharmacare on Monday.

Purdue Pharma L.P., a U.S. limited partnership, its general partner and its subsidiaries, including Imbrium Therapeutics L.P., Adlon Therapeutics L.P., Greenfield BioVentures L.P., Avrio Health L.P., Rhodes Technologies, and Rhodes Pharmaceuticals L.P., filed for bankruptcy in September 2019.

The American College of Rheumatology published the 2020 Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases.

CHAMPS Oncology, an industry leader in cancer registry operations, launched an online education session “2020 Cancer Program Insights - Optimal Resources for Cancer Care” based on the new Commission on Cancer standards.

Frontage Holdings Corporation, a contract research organization providing integrated, science-driven, product development services, is pleased to announce the expansion of its bioanalytical laboratories in Exton, PA, through its wholly-owned subsidiary, Frontage Laboratories, Inc.

Axovant Gene Therapies Ltd. (Nasdaq: AXGT) (“Axovant”) today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’ option to purchase 2,600,000 additional common shares, at a price to the public of $3.75 per share.